Joseph has over 30 years of global pharmaceutical and biotechnology industry experience building product brands and commercializing new innovations. Currently he is the Chief Executive Officer of AuraVax Therapeutics, Inc. The company is a privately held biotechnology start-up commercializing a new inhaled nasal STING agonist platform, known as NanoSTING, for the treatment and prevention of upper respiratory disease due to viral pathogens. Prior to AuraVax, he was the Chief Operating Officer for Nature’s Toolbox, Inc. (NTx), a life sciences and bioinformatics company, located in Rio Rancho, New Mexico. Additional work experience includes leading business development for IMV Inc, product lead for several vaccines at Merck & Co, Inc, associate in venture capital & investment banking with Allen & Company Inc., and financial trainee at GE Company. He has an MBA from Cornell University and B.A. from Hamilton College.